Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing ...
Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small ...
COVID-19 impact on multiple myeloma prescribing patterns. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results